DailyIQ
Last updated8 minutes ago

CI·The Cigna Group

$282.47
-0.87 (-0.31%)
Overnight$282.53+0.06 (+0.02%)
High
$289.35
Open
$287.20
Market Cap
74.78B
52W High
$314.00
Low
$277.43
P. Close
$282.47
P/E
11.66
52W Low
$239.51
Fwd P/E
8.44
DailyIQ Est.
$352.68
Inst. Ownership
38.2%
Short Interest
2.63%
Days to Cover
3.9
Div. Yield
2.19%
Next Ex-Div
~Dec 8
Technical Score (1D)
59
BULLISH
News Sentiment
41
BEARISH
On Oct 13, CI reported that it would release its Q3 earnings next month. Analysts forecast a modest year‑over‑year decline in earnings per share. The outlook suggests a slight downward pressure on the company’s earnings trajectory. The company’s announcement and the analysts’ forecast were the only developments reported for that date.
LOW TARGET
$288 +1.9%
2 analysts
MEAN TARGET
$342 +21.1%
17 analysts
HIGH TARGET
$400 +41.6%
17 analysts
PRICE RANGE
$288.00 - $400.00
SB / B / H / S / SS
9/17/8/1/1
DAILYIQ EST.
$352.68 (+24.8%)
Sector
Healthcare
Industry
Healthcare Plans
Exchange
NYQ
Country
United States
Symbol
CI
Description
The Cigna Group is a U.S.-based healthcare company focused on delivering comprehensive health solutions. Its core business is divided into two primary segments: Evernorth Health Services and Cigna Healthcare. Evernorth provides a suite of coordinated health services, including pharmacy benefits management, care delivery solutions, and other related offerings to various clients. Cigna Healthcare offers a range of medical, dental, and behavioral health insurance products and services to individuals, seniors, and employer groups, both domestically and internationally. The company distributes its products through brokers, direct sales, and exchanges, catering to a diverse customer base. Originally founded in 1792 and headquartered in Connecticut, The Cigna Group has evolved to meet the complex needs of the healthcare market.
Bought (1Y)
0 shares
$0
Sold (1Y)
226,236 shares
$65.9M
Neville EverettSee Remarks
Sell617 shares2026-09-03
Evanko Brian CSee Remarks
Award/Grant6,716 shares2026-09-01
Evanko Brian CSee Remarks
Award/Grant3,113 shares2026-09-01
Kurian George-
Award/Grant108.664 shares2026-08-31
Jones Nicole SSee Remarks
Sell2,677 shares2026-08-18
66/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Net Margin
2.2%
Revenue CAGR
23.9%
Current Ratio
0.85x
Debt / Equity
0.75x
Return on Equity
14.3%
Earnings Summary
The Cigna Group is a U.S.-based healthcare company that delivers comprehensive health solutions through its Evernorth Health Services and Cigna Healthcare segments, operating primarily in the healthcare plans sector. The firm focuses on insurance products, pharmacy benefits management, and coordinated care services for individuals, seniors, and employer groups. In the most recent quarter, Q4 2025, Cigna reported EPS of $8.08 versus an estimate of $7.50, a modest beat, while revenue surged to $72.5 billion against an estimate of $66.4 billion, marking a 7.8% YoY increase. The preceding quarter, Q3 2025, also saw an EPS beat ($7.83 vs. $7.64) and revenue growth to $69.7 billion, a 5.6% YoY rise. Compared to the prior two quarters (Q1–Q2 2025), the company accelerated its revenue growth from 3.8% to 5.6% and maintained EPS beats in all four quarters, indicating consistent earnings strength. Historically, Cigna has posted steady YoY revenue growth of roughly 4–6% over the past five years, with EPS consistently beating analyst expectations in 3 of the last 4 quarters; the company’s revenue has outpaced EPS growth in several periods, underscoring a robust top‑line trajectory. Recent news highlights the launch of HealthSense, a personalized support platform expected to cut health‑care spending by 10% by 2030, and a Piper Sandler upgrade to a $370 price target citing confidence in earnings outlook. These developments suggest a focus on cost‑efficiency and value creation. Key will be whether the company sustains its revenue acceleration while maintaining EPS beats in the next reporting cycle.

EPS

EstBeatMiss
$7.01$7.32$7.62$7.92$8.22Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$7.51 - -
Q2'26$7.83$7.78-0.6%
Q1'26$7.61$7.79+2.4%
Q4'25$7.50$8.08+7.8%
Q3'25$7.64$7.83+2.5%
Q2'25$7.15$7.20+0.6%

Revenue

EstBeatMiss
$64.9B$67.7B$70.6B$73.4B$76.2BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$74.9B - -
Q2'26$72.4B$71.6B-1.2%
Q1'26$66.2B$68.5B+3.5%
Q4'25$66.4B$72.5B+9.2%
Q3'25 - $69.7B -
Q2'25 - $67.2B -

Market Data

CI Stock Snapshot

NEUTRAL59/100
$282.53+$0.06 (0.0%)
Market cap
74.78B
P/E ratio
11.7
Day range
$277.43 – $289.35
News sentiment
41/100 · Neutral
Analyst target
$342.29 (+21.2%)
Consensus
Buy · 36 analysts
52-week range+18.0% off low · -10.0% from high
$239.51$314.00
Price $282.53 DailyIQ Est. $352.68

CI sits in the middle of its 52-week range with the technical picture unresolved. Earnings and guidance carry more weight than macro data at this capitalisation.

Behaviour On Record

What CI's own history says about today's numbers

Realized volatility (21d)
25.1% 54th pct
Below its peak
-23.0%
vs 200-day average
+0.9%
Up days (1y)
52%

The Cigna Group is currently running 25.1% annualised volatility over the last 21 sessions. Measured against CI's own 13 years of daily returns rather than a market-wide average, that is the 54th percentile — close to its own typical level, against a typical reading of 24.3%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

CI is trading -23.0% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -26.1%, and the deepest was -41.5% in 2020. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +0.9% from its 200-day moving average. Against every other day in its history, that gap ranks at the 43rd percentile — close to the gap it normally carries. Over the past year CI closed higher on 52% of sessions, and it is currently 6 sessions into a rising streak.

On October specifically: over 13 years of records, CI finished the month higher 7 of 13 times, with a median return of +1.4% and an average of +1.9%. Its strongest month historically has been November at +4.8% on average, its weakest September at -1.1%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: CI has opened more than 2% away from the prior close in 80 of 3,266 sessions (2.4% of the time), with the largest gaps running +9.1% and -17.3%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, CI moved an average of 2.8% in the session after earnings, closing higher 1 of those 3 times, with a median move of -2.5% and a largest of -3.2%.

All figures computed from 3,267 daily closes between 2013-10-14 and 2026-10-09, split-adjusted, recomputed daily. Percentiles are against CI's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of CI's sector?

The Cigna Group sits in the Health Care sector, currently ranked 4th of 12 GICS sectors by relative-strength rotation score (improving).

Sector rank
#4 of 12
Sector state
Improving
Sector rotation score
73

Options Market

What is the options market pricing for CI?

CallsPuts

For The Cigna Group's nearest expiry (2026-10-16, 2 days out), open interest is put-heavy, a defensive/bearish tilt (put/call ratio of 2.73), with at-the-money implied volatility around 36.1%. The options market is pricing roughly a ±2.8% move by that expiry — a range of about $275.53–$291.55.

Put/call ratio (2026-10-16)
2.73
ATM implied volatility
36.1%
Total open interest
15,207
Expected move by 2026-10-16
±2.8% ($275.53–$291.55)

Analyst Rating Changes

Are analysts turning bullish or bearish on CI?

Piper Sandler most recently reiterated its rating on The Cigna Group to Overweight on Oct 2, 2026 with a price target of $370 (from $346). Over the last 90 days, coverage has run 0 upgrades against 2 downgrades, a net bearish lean.

Latest action
Piper Sandler — Overweight
90-day upgrades
0
90-day downgrades
2
Net rating momentum
-2
DateFirmActionRatingPrice target
Oct 2, 2026Piper SandlerMaintainedOverweight$346 → $370
Oct 1, 2026RBC CapitalReiteratedOutperform$337
Aug 4, 2026JefferiesDowngradeBuy → Hold$336 → $307
Aug 3, 2026Raymond JamesDowngradeStrong Buy → Outperform$350 → $320
Jul 31, 2026Wells FargoMaintainedEqual-Weight$305 → $307
Jul 31, 2026GuggenheimMaintainedBuy$338 → $361
Jul 31, 2026BarclaysMaintainedEqual-Weight$304 → $310
Jul 9, 2026BernsteinMaintainedOutperform$371 → $381
Jun 8, 2026MizuhoMaintainedOutperform$330 → $340
May 26, 2026BarclaysDowngradeOverweight → Equal-Weight$310 → $304
May 22, 2026UBSMaintainedBuy$375 → $400
May 20, 2026Morgan StanleyMaintainedOverweight$355 → $361

Peers & ETF holders

CI peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

41/100
Strong NegativeNeutralStrong Positive
BEARISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
CI reported that it would release Q3 earnings next month. Analysts forecast a modest year‑over‑year decline in EPS. The outlook suggests a slight downward pressure on the company’s earnings trajectory.
What did this article say?
The Cigna Group (CI) scheduled the release of its third‑quarter 2026 financial results for November 5, 2026, with a conference call to follow at 8:30 a.m. ET. The company provided call‑in numbers, a replay window, and a live webcast link for investors. The announcement outlined the timing and logistics of the earnings release and related investor communications.
What did this article say?
Cigna Healthcare, the benefits arm of The Cigna Group (NYSE: CI), announced on October 6, 2026, the launch of Health Sense, a personalized support system that integrates health, care, benefits, and cost data for individual members. The platform is designed to enable earlier intervention and more efficient use of benefits, with projections that it could reduce overall health‑care spending by 10% by 2030. By addressing inefficiencies such as duplicate services and administrative complexity, Health Sense aims to improve both affordability for employers and health outcomes for patients.
What did this article say?
Cigna Group (CI) posted a 20‑year annualized return of 10.13%, outperforming the market by 1.05%. The insurer’s market capitalization stood at $71.48 billion as of the reporting date, underscoring its long‑term growth trajectory.
What did this article say?
Piper Sandler increased its price target for Cigna Group (CI) to $370 from $346, reflecting confidence in the insurer’s earnings outlook. The brokerage maintained an overweight rating, citing robust revenue growth and a solid balance sheet. The upgrade signals a modest bullish stance on CI’s valuation, but the move is not considered a transformative catalyst.
What did this article say?
Piper Sandler’s analyst Jessica Tassan upgraded Cigna Group (CI) to an Overweight rating and increased the price target from $346 to $370. The move reflects confidence in the insurer’s financial performance and strategic outlook.
What did this article say?
Cigna reaffirmed its long‑term adjusted EPS growth compound annual growth rate of 10% to 14% during its investor day, citing a 6% to 9% earnings growth and a 4% to 5% contribution from capital deployment. Management projected 2030 adjusted EPS of at least $45, assuming lower‑end growth for each segment. The company identified its Specialty and Care Services segment as a key driver, driven by specialty drug expansion, and noted the Pharmacy Benefit Services business as a focus under its new Signature rebate‑free model.
What did this article say?
Jefferies reduced its price target for Cigna Group (CI) from $307 to $288 while keeping a hold rating. The downgrade reflects a reassessment of the company’s valuation relative to peers. Analysts noted that the new target still places CI above the market average. The adjustment signals a modest negative outlook for the stock, though the overall stance remains unchanged.

Technical Analysis

Real-time indicators across multiple timeframes

59
NEUTRAL
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $27.35B combined position · 16 adding, 9 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy26,173,5779.89%$7.20B2026-01-29
BlackRock, Inc.▲ Buy23,438,2508.86%$6.46B2026-08-07
FMR LLC (Fidelity)▼ Sell8,018,1893.03%$2.21B2026-08-13
Geode Capital Management, LLC▲ Buy6,268,3472.37%$1.72B2026-08-12
JPMorgan Chase & Co▼ Sell5,194,3631.96%$1.45B2026-08-12
Morgan Stanley▲ Buy3,690,8121.39%$1.02B2026-08-13
Norges Bank▼ Sell3,562,6991.35%$982.16M2026-08-12
Bank of America Corp▼ Sell3,002,3661.13%$827.69M2026-08-14
Northern Trust Corp▲ Buy2,730,6871.03%$752.80M2026-08-13
Invesco Ltd.▼ Sell2,403,6120.91%$662.63M2026-08-14
Davis Selected Advisers▲ Buy2,253,4240.85%$621.24M2026-08-11
Goldman Sachs Group Inc▲ Buy1,990,4080.75%$548.72M2026-08-14
Two Sigma Investments, LP▲ Buy1,813,1100.68%$499.84M2026-08-14
AQR Capital Management LLC▼ Sell1,436,5560.54%$396.03M2026-08-14
Capital World Investors▲ Buy1,325,5830.50%$365.44M2026-08-12
Capital Research Global Investors▼ Sell1,234,4480.47%$340.31M2026-08-12
Neuberger Berman Group LLC▲ Buy728,7170.28%$201.17M2026-08-13
Susquehanna International Group, LLP▲ Buy632,9080.24%$174.48M2026-08-14
Wells Fargo & Company▼ Sell594,1070.22%$163.78M2026-08-14
Prudential Financial Inc▲ Buy512,2540.19%$141.22M2026-08-12
Citigroup Inc▲ Buy490,3030.19%$135.17M2026-08-03
Millennium Management LLC▲ Buy455,6450.17%$125.61M2026-08-14
Squarepoint Ops LLC▲ Buy451,3890.17%$124.44M2026-08-14
Man Group plc▲ Buy419,8170.16%$115.74M2026-08-14
Glenview Capital Management, LLC▼ Sell412,2230.16%$113.64M2026-08-14
Q2 2026 flow:3.76M sh bought ($1.04B)5.34M sh sold ($1.47B)net -1.58M sh (−$437.72M)
Congressional Trading Activity
25 disclosed trades · ~$249.0K est. traded value · 9 buys, 16 sells
MemberChamberStateTypeAmountTradedFiled
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
Jared MoskowitzHouseFL23▼ Sell$1K - $15K2026-03-232026-04-30
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2026-03-132026-04-07
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-12-192026-01-12
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-12-182026-01-15
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-11-132025-12-11
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-11-122025-12-15
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-09-252025-10-07
Valerie HoyleHouseOR04▼ Sell$1K - $15K2025-09-232025-10-10
Julie JohnsonHouseTX32▲ Buy$1K - $15K2025-09-232026-08-05
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-09-232026-08-05
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-08-142025-09-11
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-08-052025-09-12
Jared MoskowitzHouseFL23▲ Buy$1K - $15K2025-05-152025-06-27
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-05-122025-06-22
Julia LetlowHouseLA05▼ Sell$1K - $15K2025-04-222026-01-13
Julie JohnsonHouseTX32▲ Buy$1K - $15K2025-03-192025-04-14
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-03-032025-04-14
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-02-252025-03-27
Jefferson ShreveHouseIN06▲ Buy$15K - $50K2025-02-242025-03-09
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-01-242025-02-11
Julie JohnsonHouseTX32▲ Buy$1K - $15K2025-01-152025-02-12
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-01-132025-02-13
Valerie HoyleHouseOR04▲ Buy$1K - $15K2024-10-292025-09-12
Julia LetlowHouseLA05▲ Buy$1K - $15K2024-10-232026-01-13